Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 13, 2004 - Issue 10
Submit an article Journal homepage
172
Views
18
CrossRef citations to date
0
Altmetric
Drug Evaluation

Ciclesonide: a novel inhaled corticosteroid

Marc Humbert Hôpital Antoine Béclère, Service de Pneumologie et Réanimation Respiratoire, Assistance Publique Hôpitaux de Paris, Université Paris-Sud, 157 Rue de la Porte de Trivaux, 92140 Clamart. [email protected]
Pages 1349-1360 | Published online: 24 Feb 2005

Bibliography

  • LIN H, CASALE TB: Treatment of allergic asthma. Am. I Med. (2002) 113(Suppl. 9A):8S–16S.
  • KHERADMAND F, RISHI K, CORRY DB: Environmental contributions to the allergic asthma epidemic. Environ. Health. Perspect. (2002) 110\(Suppl. 4):553–556.
  • MANNINO DM, HOMA DM, AKINBAMI LJ, MOORMAN JE, GWYNN C, REDD SC: Surveillance for asthma-United States, 1980-1999. MMWR. Surveil]. Summ. (2002) 51:1–13.
  • REDD SC: Asthma in the United States: burden and current theories. Environ. Health. Perspect. (2002) 110\(Suppl. 4):557–560.
  • Self-reported asthma prevalence and control among adults-United States, 2001. MMWR. Morb. Mortal. Wkly Rep. (2003) 52:381–384.
  • NATIONAL ASTHMA EDUCATION AND PREVENTION PROGRAM. EXPERT PANEL REPORT: Guidelines for the diagnosis and management of asthma update on selected topics-2002. J. Allergy Clio. Immunol (2002) 110(5 Suppl.):S141–S219.
  • ••Recent asthma guidelines.
  • ALLEN DB, BIELORY L, DERENDORF H, DLUHY R, COLICE GL, SZEFLER SJ: Inhaled corticosteroids: past lessons and future issues. j. Allergy Clio. Immunol (2003) 112(Suppl.):S1–S40.
  • ROHATAGI S, APPAJOSYULA S, DERENDORF H et al.: Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J. Clio. Pharmacol (2004) 44:37–47.
  • •Comprehensive review on ICS pharmacokinetics and pharmacodynarnics.
  • DE LONGUEVILLE M: What are the candidate groups for pharmacotherapeutic intervention to prevent asthma? Pediatr. Allergy Immunol (2000) (Suppl. 13):41–44.
  • FOUCARD T: Is prevention of allergy and asthma possible? Acta Paediatr. Sapp]. (2000) 89:71–75.
  • BECKER AB, CHAN-YEUNG M: Primary prevention of asthma. Curt: Opin. Palm. Med. (2002) 8:16–24.
  • BHALAY G, SANDHAM DA: Recent advances in corticosteroids for the treatment of asthma. Curr. Opin. Investig. Drugs (2002) 3:1149–1156.
  • RODRIGO GJ: Inhaled therapy for acute adult asthma. Cum Opin. Allergy Clio. Immunol (2003) 3:169–175.
  • UMLAND SP, SCHLEIMER RP, JOHNSTON SL: Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Palm. Pharmacol. Ther. (2002) 15:35–50.
  • PELAIA G, VATRELLA A, CUDA G, MASELLI R, MARSICO SA: Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases. Life. Sci. (2003) 72:1549–1561.
  • CAVE A, ARLETT P, LEE E: Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects. Pharmacol The]: (1999) 83:153–179.
  • LIPWORTH BJ: Systemic adverse effects of inhaled corticosteroid therapy. A systematic review and meta-analysis. Arch. Intern. Med. (1999) 159:941–955.
  • ••Detailed analysis of ICS systemic effects.
  • CAMPBELL LM: Once-daily inhaled corticosteroids in mild to moderate asthma. Improving acceptance of treatment. Drugs (1999) 58\(Suppl. 4):25–33.
  • Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl. I Med. (2000) 343:1054–1063.
  • JACKSON LD, POLYGENIS D, MCI VOR RA, WORTHINGTON I: Comparative efficacy and safety of inhaled corticosteroids in asthma. Can. Clio. Pharmacol (1999) 6:26–37.
  • KELLY HW, NELSON HS: Potential adverse effects of the inhaled corticosteroids. I Allergy Clio. Immunol. (2003) 112:469–478.
  • DUBUS JC, MARGUET C, DESCHILDRE A et al.: Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device. Allergy (2001) 56:944–948.
  • JOGUPARTHI V, BREEN P, COMPADRE C et al: Effect of propellant on the pharmacokinetics and pharmacodynamics of inhaled albuterol in asthmatic subjects. Aerosol. Med. (2003) 16:47–53.
  • GOLDIN JG, TASHKIN DP, KLEERUP EC et al.: Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. Allergy Clio. Immunol (1999) 104:S258–S267.
  • CORREN J, TASHKIN DP: Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma. Clio. The]: (2003) 25:776–798.
  • LEACH CL, DAVIDSON PJ, BOUDREAU RJ: Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur. Respir. J. (1998) 12:1346–1353.
  • SUISSA S, BALTZAN M, KREMER R, ERNST P: Inhaled and nasal corticosteroid use and the risk of fracture. Am. I Respir. Crit. Care. Med. (2004) 169:83–88.
  • HUBBARD RB, SMITH CJ, SMEETH L, HARRISON TW, TATTERSFIELD AE: Inhaled corticosteroids and hip fracture: a population-based case-control study. Am. .1 Respir. Crit. Care. Med. (2002) 166:1563–1566.
  • •Analysis of ICS bone effects.
  • ANHOJ J, BISGAARD AM, BISGAARD H: Systemic activity of inhaled steroids in 1- to 3-year-old children with asthma. Pediatrics (2002) 109:E40.
  • MEALY NE, BAYES M, CASTANER J: Ciclesonide. Drugs Fut. (2001) 26:1033–1039.
  • DIETZEL K, ENGELSTATTER R, KELLER A: Ciclesonide: an on-site-activated steroid. In: New Drugs for Asthma, Allergy and COPD. TT Hansel, PJ Barnes (Eds), Karger, Basel, Switzerland (2001) 31:91–93.
  • MUTCH E, NAVE R, ZECH K, WILLIAMS FM: Esterases involved in the hydrolysis of ciclesonide in human tissues. Ear: Respir (2003) 22\(Suppl. 45):267s.
  • BETHKE T, NAVE R, ZECH K, GUNAWARDENA K: Pharmacokinetics of ciclesonide and its active principle in asthma patients and healthy subjects after single dose inhalation. I Allergy Clin. Immunol (2003) 111:S217.
  • BERGER WE, MANSFIELD L, PINTER C et al.: Ciclesonide is well tolerated and has minimal oropharyngeal side effects at once-daily doses of 80 pg, 160 pg, and 320 pg in the treatment of patients with mild-to-moderate asthma. Allergy Clin. Immunol (2004) 113:S38.
  • PAUWELS RA, DEROM E, VAN DE VELDE V, MARISSENS S, VINCKEN W: Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and PC20 for adenosine in asthma patients [poster]. Proceedings of the 98th International Conference of the American Thoracic Society (ATS). Atlanta, Georgia, USA (2002).
  • NAVE R, DROLLMANN A, MEYER W, ZECH K: In vivo epimeric stability of ciclesonide. Am. Respir. Crit. Care Med. (2003) 167:A771.
  • STOECK M, RIEDEL R, HOCHHAUS G et al: In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. Pharmacol Exp. Ther. (2004) 309:249–258.
  • DERENDORF H: Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir. Med. (1997) 91(Suppl. A):22–28.
  • BUNDSCHUH DS, MARX D, HATZELMANN A et al.: Preclinical anti-inflammatory activity and safety profile of the novel glucocorticoid ciclesonide. Proceedings of the 11th Annual Congress of the European Respiratory Socien, (ERA Berlin, Germany (2001).
  • BELVISI MG, BUNDSCHUH DS, STOECK M et al: Preclinical M vivo assessment of ciclesonide, a novel corticosteroid for the treatment of asthma Proceedings of the 11th Annual Congress of the European Respiratory Socien, (ERA Berlin, Germany (2001).
  • ROHATAGI S, ARYA V, ZECH K et al:Population pharmacokinetics and pharmacodynamics of ciclesonide. ./. Clin. Pharmacol (2003) 43:365–378.
  • •Review article.
  • ROHATAGI S, DERENDORF H, ZECK K: PK/PD of inhaled corticosteroids: the risk/benefit of inhaled ciclesonide. .1 Allergy Clin. Immunol (2003) 111:S218.
  • NAVE R, BETHKE TD, VAN MARLE SP, ZECH K: Pharmacokinetics of [MC]-ciclesonide after oral and intravenous administration to healthy subjects. Clin. Pharmacokinet. (2004) 43:479–486.
  • NAVE R, BETHKE TD, SEIBERLING M, STEINIJANS VW, ZECH K: Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects. Eur. Respir. (2002) 20\(Suppl. 38):110s.
  • NAVE R, ZECH K, BETHKE TD: Oropharyngeal deposition of inhaled ciclesonide and budesonide in healthy subjects. Allergy Clin. Immunol (2003) 111:S220.
  • RICHTER K, NAVE R, BIBERGER C, BETHKE T, MAGNUSSAN H: Low oropharyngeal deposition of inhaled ciclesonide in healthy subjects and asthma patients. Proceedings of the 4th Triennial World Asthma Meeting 2004 (WAM). Bangkok, Thailand (2004).
  • RICHTER K, NIELSEN-GODE D, BIBERGER C, NAVE R, MAGNUSSEN H: Oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in asthmatics. Proceedings of the 98th International Conference of the American Thoracic Society (ATS). Atlanta, Georgia, USA (2002).
  • HALL M, PEET CE BODDINGTON TKS, ENOS T, NAVE R, ZECH K: Enzymology of thehuman hepatic metabolism of ciclesonide (B9207-015). Proceedings of the 15th Annual Meeting of the Japanese Society for the Study of Xenobiotics. Fukuoka, Japan (2000).
  • NAVE R, SATTELE N, MEYER W, FUHST R, ZECH K: Formation of fatty acid conjugates of ciclesonide-active principle in the rat lung after 4-week inhalation of ciclesonide. Am. .1 Respir. Crit. Care Med. (2003) 167:A771.
  • NAVE R, FISHER R, ZECH K: In vitro metabolism of ciclesonide in the human lung and liver as determined by use of precision-cut tissue slices. Am. Respir. Crit. Care Med. (2003) 167:A771.
  • LARSEN BB, NIELSEN LP, ENGELSTATTER R, STEINIJANS V, DAHL R: Effect of ciclesonide on allergen challenge in subjects with bronchial asthma. Allergy (2003) 58:207–212.
  • •Inhaled ciclesonide in allergen-induced asthma.
  • KANNIESS F, RICHTER K, BOHME S, JORRES RA, MAGNUSSEN H: Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Palm. Pharmacol Ther. (2001) 14:141–147.
  • TAYLOR DA, JENSEN MW, KANABAR V et al.: A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5'-monophosphate in asthmatic patients. Am. I Respir. Crit. Care Med. (1999) 160:237–243.
  • •Effects of inhaled ciclesonide on airway hyper-responsiveness to AMP.
  • POSTMA DS, SEVETTE C, MARTINAT Y, SCHLOSSER N, AUMANN J, KAFE H: Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Ear: Respir.1. (2001) 17:1083-1088.
  • •Analysis of morning and evening once-daily inhaled ciclesonide.
  • WEINBRENNER A, HONEKE D, ZSCHIESCHE M et al.: Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. Clin. Endocrinol Metab. (2002) 87:2160–2163.
  • •Serum corticosol measurements on inhaled ciclesonide.
  • ENGELSTATTER R, LANGDON C, BETHKE T, RATHGEB F, STEINIJANS VW, WURST W: Efficacy of ciclesonide after twelve-week treatment of bronchial asthma [poster]. Proceedings of the 98th International Conference of the American Thoracic Society Atlanta, Georgia, USA (2002).
  • CHAPMAN KR, PATEL P, D'URZO AD et al.: Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy(2004) (In press).
  • LANGDON CG, ADLER M, MEHRA S, DROLLMANN A: Ciclesonide is effective in the treatment of asthma: a 12-week, placebo-controlled study. Proceedings of the 4th Triennial World Asthma Meeting 2004 (WAM). Bangkok, Thailand (2004).
  • O'CONNOR B, SIPS P, ENGELSTATTER R, STEINIJANS VW, WURST W: Management of moderate to severe bronchial asthma by ciclesonide: a 12-week trial. Proceedings of the 98th International Conference of the American Thoracic Society (ATS). Atlanta, Georgia, USA (2002).
  • UKENA D, BIBERGER C, VON BEHREN V et al.: Ciclesonide significantly improves pulmonary function when compared with budesonide: a randomized 12-week study. Ear: Respic (2003) 22\(Suppl. 45):411s.
  • BOULET L-P, ENGELSTATTER R, MAGYAR P, TIMAR M, KNIGHT A, FABBRI L: Ciclesonide is at least as effective as budesonide in the treatment of patients with bronchial asthma. Am. J. Respic Crit. Care Med. (2003) 167:A771.
  • ENGELSTATTER R, BENEZET 0, KAFE. H et al: Comparative study in asthma patients treated with inhaled ciclesonide (80 pg or 320 pg once daily) or budesonide (200 pg twice daily) for 12 weeks. Am. j Respic Grit. Care Med. (2003) 167:A771.
  • BUHL R, VINKLER I, MAGYAR P et al.: Once daily ciclesonide is as effective as fluticasone propionate given twice daily in treating patients with asthma. Am. I Respic Grit. Care Med. (2004) 169:A91.
  • CHAPMAN KR, PATEL P, BOULET LP et al.: Efficacy and long-term safety of ciclesonide in asthmatic patients as demonstrated in a 52 week long study. Eur. Respic J. (2002) 20\(Suppl. 38):373s.
  • O'CONNOR BJ, KILFEATHER S, CHEUNG D et al: Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks. Ear: Respic J. (2002) 20\(Suppl. 38):406s.
  • SZEFLER SJ, HERRON J, LLOYD M et al.: High doses of the novel inhaled steroid ciclesonide have no effect on HPA-axis function in patients with moderate-to-severe persistent asthma. Allergy Clin. Immunol (2003) 111:S216.
  • LAFORCE CF, BAKER JW, AMIN D et al.: Ciclesonide, a novel inhaled steroid, has no effect on hypothalamic-pituitary-adrenal (HPA)-axis function in mild-to- moderate asthmatics. Allergy Clin. Irnmunol. (2003) 111:S218.
  • BERNSTEIN JA, NOONAN M, RIM C et al.: Ciclesonide has minimal oropharyngeal side effects in the treatment of patients with moderate-to-severe asthma. Allergy Clin. Immunol (2004) 113:S113.
  • KALINER M, WHITE M, CHERVINSKY P et al: Ciclesonide, a novel inhaled corticosteroid (ICS), does not suppress hypothalamic-pituitary-adrenal (HPA)-axis function. Proceedings of the World Allergy Organization Congress-XVIII ICACI Vancouver, Canada (2003) (Abstract 0-17–1).
  • MARTIN RJ, SZEFLER SJ, CHINCHILLI VM et al: Systemic effect comparisons of six inhaled corticosteroid preparations. Am. I Respic Grit. Care. Med. (2002) 165:1377–1383.

Websites

  • http://www.ginasthma.com/wr_clean.pdf National Institutes of Health. Global Initiative for Asthma®: Global Strategy for Asthma Management and Prevention. Updated 2003.
  • http://www.who.int/mediacentre/ factsheets/fs206/en/print.html World Health Organization. Fact Sheet 206. Bronchial asthma (2000).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.